- Home
- GLSI vs III Comparison
GLSI vs III Comparison
Compare GLSI & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- III
- Stock Information
- Founded
- GLSI 2006
- III 2006
- Country
- GLSI United States
- III United States
- Employees
- GLSI N/A
- III N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- III Professional Services
- Sector
- GLSI Health Care
- III Consumer Discretionary
- Exchange
- GLSI Nasdaq
- III Nasdaq
- Market Cap
- GLSI 159.8M
- III 178.1M
- IPO Year
- GLSI 2020
- III 2007
- Fundamental
- Price
- GLSI $11.95
- III $3.06
- Analyst Decision
- GLSI Strong Buy
- III Buy
- Analyst Count
- GLSI 1
- III 1
- Target Price
- GLSI $38.00
- III $3.75
- AVG Volume (30 Days)
- GLSI 24.6K
- III 71.2K
- Earning Date
- GLSI 04-14-2025
- III 03-06-2025
- Dividend Yield
- GLSI N/A
- III 5.73%
- EPS Growth
- GLSI N/A
- III N/A
- EPS
- GLSI N/A
- III N/A
- Revenue
- GLSI N/A
- III $255,994,000.00
- Revenue This Year
- GLSI N/A
- III N/A
- Revenue Next Year
- GLSI N/A
- III N/A
- P/E Ratio
- GLSI N/A
- III N/A
- Revenue Growth
- GLSI N/A
- III N/A
- 52 Week Low
- GLSI $10.52
- III $2.92
- 52 Week High
- GLSI $21.44
- III $4.40
- Technical
- Relative Strength Index (RSI)
- GLSI 40.69
- III 38.83
- Support Level
- GLSI $11.87
- III $3.12
- Resistance Level
- GLSI $12.95
- III $3.29
- Average True Range (ATR)
- GLSI 0.59
- III 0.10
- MACD
- GLSI -0.05
- III -0.01
- Stochastic Oscillator
- GLSI 25.19
- III 13.33
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.